Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Harrow, Inc. Common Stock

HROW

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Last trade $29.16
Day change +$0.07 (+0.24%)
Day range $28.81 – $29.69
Volume 225,841
Market cap $1.09B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.09B
Price / earnings
—
Price / book
37.41×
Price / sales
3.6×
EV / sales
4.32×
EV / EBITDA
80.11×

Profitability

Earnings per share
-$0.76
Return on assets
-6.43%
Return on equity
-97.6%
Dividend yield
0%

Liquidity and leverage

Debt / equity
10.03×
Current ratio
2.29×
Quick ratio
2.12×
Cash ratio
0.66×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.35M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HROW, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$99.3M$70.66M$44.2M$89.09M$71.64M$63.74M$47.83M$66.83M
Cost of revenue$24.39M$20.3M$17.16M$18.47M$17.71M$16.23M$15.52M$14.14M
Gross profit$74.9M$50.36M$27.05M$70.62M$53.93M$47.51M$32.31M$52.7M
Selling, general and administrative$53.15M$53.3M$43.23M$43.31M$35.86M$33.24M$40.51M$34.79M
Research and development$10.29M$8.07M$5.9M$11.72M$3.32M$2.87M$3.03M$4.76M
Total operating expenses$63.43M$61.37M$49.13M$55.03M$39.18M$36.1M$43.54M$39.8M
Operating income$11.47M-$11.01M-$22.08M$15.59M$14.75M$11.41M-$11.23M$12.9M
Interest expense-$6.21M-$6.26M-$5.5M-$5.19M-$6.04M-$6.41M-$6.55M-$6.38M
Income before taxes$10.26M-$17.27M-$27.58M$10.4M$1.02M$5M-$17.78M$6.26M
Income taxes$506K$0$25K$3.77M$0$0$0-$514K
Net income$9.76M-$17.27M-$27.6M$6.63M$1.02M$5M-$17.78M$6.78M
Net income attributable to common shareholders$9.76M-$17.27M-$27.6M$6.63M$1.02M$5M-$17.78M$6.78M
EBITDA$17.49M-$5.02M-$16.5M$20.37M$19.46M$16.13M-$6.54M$17.7M
Basic earnings per share$0.26-$0.46-$0.74$0.18$0.03$0.14-$0.50$0.19
Diluted earnings per share$0.25-$0.46-$0.74$0.20$0.03$0.13-$0.50$0.19

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say

Harrow (HROW) reported Q3 2026 revenue of $99.3 million, up 38.6% year-over-year and slightly beating the consensus estimate of $98.44 million. However, EPS came in at $0.12, missing the consensus estimate of $0.13. The stock has underperformed the broader market, declining 8.4% over the past month, and carries a Zacks Rank #5 (Strong Sell) rating.

Zacks Investment Research

Harrow (HROW) Q3 Earnings Lag Estimates

Harrow (HROW) reported Q3 2026 earnings of $0.12 per share, missing the consensus estimate of $0.13 and falling short of prior year's $0.33. The pharmaceutical company posted revenues of $99.3 million, slightly beating expectations. However, the stock has declined 45.1% year-to-date and received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions, suggesting continued underperformance ahead.

Zacks Investment Research

Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates

Profound Medical reported a quarterly loss of $0.21 per share, missing the consensus estimate of $0.19 loss, with an earnings surprise of -10.53%. Revenue of $9.83 million slightly exceeded expectations by 0.31%, but the company has underperformed the S&P 500 by 21.3% year-to-date. Despite the miss, the stock maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.

Zacks Investment Research

Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Prelude Therapeutics (PRLD) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +9.72% and Zacks Rank #2. The company is projected to report a quarterly loss of $0.14 per share (improved 46.2% year-over-year) on revenues of $5 million (down 23.1%). With a strong history of beating consensus estimates in the last four quarters, PRLD appears positioned for an earnings beat.

Zacks Investment Research

Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?

Harrow (HROW) is expected to report Q3 2026 earnings on November 9 with a consensus EPS estimate of $0.17 (down 48.5% YoY) but revenues of $99.88M (up 39.4% YoY). With a +44.00% Earnings ESP and Zacks Rank #3, analysts predict the company will likely beat consensus estimates. Pacira BioSciences (PCRX) is also expected to beat estimates with a +0.87% Earnings ESP and Zacks Rank #3.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 8, 20131-for-5reverse split